These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 20028419)

  • 1. Comparison of kaolin and tissue factor activated thromboelastography in haemophilia.
    Young G; Zhang R; Miller R; Yassin D; Nugent DJ
    Haemophilia; 2010 May; 16(3):518-24. PubMed ID: 20028419
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimizing thrombelastography (TEG) assay conditions to monitor rFVIIa (NovoSeven) therapy in haemophilia A patients.
    Viuff D; Andersen S; Sørensen BB; Lethagen S
    Thromb Res; 2010 Aug; 126(2):144-9. PubMed ID: 20542542
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluating and monitoring the efficacy of recombinant activated factor VIIa in patients with haemophilia and inhibitors.
    Qi X; Zhao Y; Li K; Fan L; Hua B
    Blood Coagul Fibrinolysis; 2014 Oct; 25(7):754-60. PubMed ID: 24806320
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Evaluation of thromboelastography for monitoring recombinant activated factor VII ex vivo in haemophilia A and B patients with inhibitors: a multicentre trial.
    Young G; Ebbesen LS; Viuff D; Di Paola J; Konkle BA; Negrier C; Pasi J; Ingerslev J
    Blood Coagul Fibrinolysis; 2008 Jun; 19(4):276-82. PubMed ID: 18469548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Intra-patient variability of thromboelastographic parameters following in vivo and ex vivo administration of recombinant activated factor VII in haemophilia patients. A multi-centre, randomised trial.
    Kenet G; Stenmo CB; Blemings A; Wegert W; Goudemand J; Krause M; Schramm W; Kirchmaier C; Martinowitz U
    Thromb Haemost; 2010 Feb; 103(2):351-9. PubMed ID: 20024491
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feasibility of using thrombin generation assay (TGA) for monitoring bypassing agent therapy in patients with hemophilia having inhibitors.
    Ay Y; Balkan C; Karapinar DY; Akin M; Bilenoglu B; Kavakli K
    Clin Appl Thromb Hemost; 2013; 19(4):389-94. PubMed ID: 22395575
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The pharmacokinetics and pharmacodynamics of single-dose and multiple-dose recombinant activated factor VII in patients with haemophilia A or B.
    Fernández-Bello I; Stenmo C; Butta N; Lind V; Ezban M; Jiménez-Yuste V
    Haemophilia; 2017 Nov; 23(6):868-876. PubMed ID: 28851065
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Thromboelastography and recombinant factor VIIa-hemophilia and beyond.
    Sørensen B; Ingerslev J
    Semin Hematol; 2004 Jan; 41(1 Suppl 1):140-4. PubMed ID: 14872435
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Variability of thromboelastographic responses following the administration of rFVIIa to haemophilia A dogs supports the individualization of therapy with a global test of haemostasis.
    Othman M; Powell S; Hopman WM; Lillicrap D
    Haemophilia; 2010 Nov; 16(6):919-25. PubMed ID: 20609015
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clot lysis phenotype and response to recombinant factor VIIa in plasma of haemophilia A inhibitor patients.
    Bakhtiari K; Kamphuisen PW; Mancuso ME; Hamulyak K; Schutgens RE; Santagostino E; Meijers JC
    Br J Haematol; 2013 Sep; 162(6):827-35. PubMed ID: 23889493
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Factor VIIa analogue (V158D/E296V/M298Q-FVIIa) normalises clot formation in whole blood from patients with severe haemophilia A.
    Sørensen B; Persson E; Ingerslev J
    Br J Haematol; 2007 Apr; 137(2):158-65. PubMed ID: 17391496
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Thrombin generation and platelet activation induced by rFVIIa (NovoSeven) and NN1731 in a reconstituted cell-based model mimicking haemophilia conditions.
    Aljamali MN; Kjalke M; Hedner U; Ezban M; Tranholm M
    Haemophilia; 2009 Nov; 15(6):1318-26. PubMed ID: 19659796
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Thrombin generation and fibrinolysis in anti-factor IX treated blood and plasma spiked with factor VIII inhibitor bypassing activity or recombinant factor VIIa.
    Bolliger D; Szlam F; Molinaro RJ; Escobar MA; Levy JH; Tanaka KA
    Haemophilia; 2010 May; 16(3):510-7. PubMed ID: 20050927
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of factor VIII inhibitor bypassing activity (FEIBA), recombinant factor VIIa or both on thrombin generation in normal and haemophilia A plasma.
    Livnat T; Martinowitz U; Zivelin A; Seligsohn U
    Haemophilia; 2008 Jul; 14(4):782-6. PubMed ID: 18371162
    [TBL] [Abstract][Full Text] [Related]  

  • 15. An in-vitro assessment of tranexamic acid as an adjunct to rFVIII or rFVIIa treatment in haemophilia A.
    Rea CJ; Foley JH; Bevan DH; Sørensen B
    Ann Hematol; 2014 Apr; 93(4):683-92. PubMed ID: 24193375
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
    Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
    Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming delayed in-vitro response to rFVIIa: effects of rFVIIa and rFVIIa analogue (vatreptacog alfa) concentration escalation in whole blood assays.
    Brophy DF; Martin EJ; Barrett JC; Nolte ME; Kuhn JG; Hedner U; Ezban M
    Blood Coagul Fibrinolysis; 2011 Sep; 22(6):541-6. PubMed ID: 21681082
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factor VIIa analog has marked effects on platelet function and clot kinetics in blood from patients with hemophilia A.
    Brophy DF; Martin EJ; Nolte ME; Kuhn JG; Barrett JC; Ezban M
    Blood Coagul Fibrinolysis; 2010 Sep; 21(6):539-46. PubMed ID: 20581663
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant activated factor VII effectively reverses the anticoagulant effects of heparin, enoxaparin, fondaparinux, argatroban, and bivalirudin ex vivo as measured using thromboelastography.
    Young G; Yonekawa KE; Nakagawa PA; Blain RC; Lovejoy AE; Nugent DJ
    Blood Coagul Fibrinolysis; 2007 Sep; 18(6):547-53. PubMed ID: 17762530
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction of human hemophilia A whole blood abnormalities with a novel bypass agent: zymogen-like FXa(I16L).
    George LA; Thalji NK; Raffini LJ; Gimotty PA; Camire RM
    J Thromb Haemost; 2015 Sep; 13(9):1694-8. PubMed ID: 26190406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.